Dova’s proprietary pipeline includes one commercial product, Doptelet, for thrombocytopenia in adults with chronic liver disease scheduled to undergo a procedure, and in thrombocytopenia patients with chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.

Dova is listed on the NASDAQ exchange under the symbol DOVA. It is currently developing three further treatments for differing indications of thrombocytopenia.